Dogma BioTech
Dogma Biotech is a biotechnology company leveraging artificial intelligence and synthetic biology to develop minimalist glycans that meet or surpass natural therapeutic efficacy. Their AI-driven platform creates streamlined glycosylation modifications that enable protein therapies to be produced up to 5 times faster and cheaper, while delivering twice the therapeutic benefits. The company has preclinical validation through animal studies in partnership with a European biopharma, demonstrating that their glycan-modified proteins match or exceed the efficacy of current commercial therapies. Dogma Biotech's approach challenges traditional glyco-engineering paradigms, aiming to unlock vast therapeutic potential in the unexplored glycomics space and reduce protein manufacturing costs significantly.
Dogma BioTech
Dogma Biotech is a biotechnology company leveraging artificial intelligence and synthetic biology to develop minimalist glycans that meet or surpass natural therapeutic efficacy. Their AI-driven platform creates streamlined glycosylation modifications that enable protein therapies to be produced up to 5 times faster and cheaper, while delivering twice the therapeutic benefits. The company has preclinical validation through animal studies in partnership with a European biopharma, demonstrating that their glycan-modified proteins match or exceed the efficacy of current commercial therapies. Dogma Biotech's approach challenges traditional glyco-engineering paradigms, aiming to unlock vast therapeutic potential in the unexplored glycomics space and reduce protein manufacturing costs significantly.